Literature DB >> 21890773

High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis.

Anastácio Q Sousa1, Mércia S Frutuoso, Elisabete A Moraes, Richard D Pearson, Margarida M L Pompeu.   

Abstract

We report for the first time the successful use of fluconazole to treat cutaneous leishmaniasis due to Leishmania braziliensis. We used escalating doses from 5 to 8 mg/kg per day. At a dose of 5 mg/kg per day, 75% patients were cured, and at 8 mg/kg per day, the cure rate was 100%. Fluconazole was well tolerated.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21890773     DOI： 10.1093/cid/cir496

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  20 in total

Review 1.  Leishmaniasis in the United States: treatment in 2012.

Authors:  Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

2.  Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.

Authors:  Adrienne J Showler; Andrea K Boggild
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

3.  Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers.

Authors:  Daniel P Eiras; Laura A Kirkman; Henry W Murray
Journal:  Curr Treat Options Infect Dis       Date:  2015-03-01

Review 4.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

5.  In Vitro Sensitivity of Cutaneous Leishmania Promastigote Isolates Circulating in French Guiana to a Set of Drugs.

Authors:  Marine Ginouvès; Stéphane Simon; Mathieu Nacher; Magalie Demar; Bernard Carme; Pierre Couppié; Ghislaine Prévot
Journal:  Am J Trop Med Hyg       Date:  2017-02-06       Impact factor: 2.345

6.  Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.

Authors:  Anny Fortin; Diana P Caridha; Susan Leed; Franklyn Ngundam; Jenell Sena; Tom Bosschaerts; Sandi Parriott; Mark R Hickman; Thomas H Hudson; Max Grogl
Journal:  PLoS Negl Trop Dis       Date:  2014-09-11

Review 7.  CYP51 as drug targets for fungi and protozoan parasites: past, present and future.

Authors:  Galina I Lepesheva; Laura Friggeri; Michael R Waterman
Journal:  Parasitology       Date:  2018-04-12       Impact factor: 3.234

8.  Fluconazole effectiveness against Leishmania (Viannia) braziliensis: is the evidence enough?

Authors:  Jaime R Torres; José A Suárez
Journal:  Clin Infect Dis       Date:  2012-04-20       Impact factor: 9.079

Review 9.  Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.

Authors:  Ludovic Reveiz; Ana Nilce Silveira Maia-Elkhoury; Rubén Santiago Nicholls; Gustavo Adolfo Sierra Romero; Zaida E Yadon
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

10.  Interventions for American cutaneous and mucocutaneous leishmaniasis.

Authors:  Mariona Pinart; José-Ramón Rueda; Gustavo As Romero; Carlos Eduardo Pinzón-Flórez; Karime Osorio-Arango; Ana Nilce Silveira Maia-Elkhoury; Ludovic Reveiz; Vanessa M Elias; John A Tweed
Journal:  Cochrane Database Syst Rev       Date:  2020-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.